Back to Clinical Trials Overview

Back To Cancer Clinical Trials

Your search for "Lung and Other Respiratory" returned 8 results:


A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination with Carboplatin and Etoposide Followed by LY2940680 versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients with Extensive-Stage Small Cell Lung Cancer
Principal Investigator(s): Jorge Gomez

Effects of a dietary supplement (SV) on advanced non small cell lung cancer patients treated with best supportive care (BSC): A randomized double-blind placebo controlled study, a phase III Trial
Principal Investigator(s): Henry Sacks

Safety and Tolerance of Intravenous 4-methyl-4cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients with Malignancies involving the Central Nervous System
Principal Investigator(s): Dr. Philip Friedlander

METformin with a caRbOhydrate restricted diet in combination with platinum based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer (NS-NSCLC) – METRO study
Principal Investigator(s): Dr. Jorge Gomez

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator(s): Dr. Jorge Gomez

A Phase II, Non-comparative, Open label, Multi-centre, International Studyof MEDI4736, in Patients with Locally Advanced or Metastatic Non-SmallCell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)
Principal Investigator(s): Dr. Jorge Gomez

A Phase III, Open-label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB IV) who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC)
Principal Investigator(s): Dr. Jorge Gomez

A PHASE III, RANDOMIZED, OPEN-LABEL, CROSSOVER, MULTI-CENTER, SAFETY AND EFFICACY STUDY TO EVALUATE NAB-PACLITAXEL (ABRAXANE®) AS MAINTENANCE TREATMENT AFTER INDUCTION WITH NAB-PACLITAXEL PLUS CARBOPLATIN IN SUBJECTS WITH SQUAMOUS CELL NON-SMALL CELL LUNG CANCER (NSCLC)
Principal Investigator(s): Dr. Jorge Gomez